Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Chief Medical Officer | April 02, 2018 | April 04, 2018 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | CHIEF MEDICAL OFFICER | March 15, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date April 02, 2018 · Filed April 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-04-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-02 · Exercise / conversion · Acquired 4,000 · Balance 4,000 Row 2 · 2018-04-02 · Sale · Disposed 4,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2025-09-22 | Direct | 22,256 |
Reported balance
After 2018-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-02 · Exercise / conversion · Disposed 4,000 · Balance 22,256 F1: 25% of the option vested on April 14, 2016 and the remaining shares vest in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option vested on April 14, 2016 and the remaining shares vest in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
Mirum Pharmaceuticals, Inc.
Report date March 15, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,864 |
Ending reported balance
After 2026-03-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-15 · Exercise / conversion · Acquired 13,334 · Balance 26,151 F1: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-03-16 · Sale · Disposed 7,287 · Balance 18,864 F2: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,666 |
Reported balance
After 2026-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-15 · Exercise / conversion · Disposed 13,334 · Balance 6,666 F1: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
F3: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 7,287 | $91.98 | $670,242.96 |
DisclosureSEC source: 0001670138-26-000005 · form4-03172026_070309.xml · nonDerivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,864 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 13,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001670138-26-000005 · form4-03172026_070309.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 13,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F3 · derivative.expiration_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 13,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001670138-26-000005 · form4-03172026_070309.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantPerformance Restricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001670138-26-000003 · form4-01302026_060106.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F4 · derivative.expiration_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 11,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001670138-26-000003 · form4-01302026_060106.xml · derivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,760 Underlying: Common Stock · 11,760 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 18,140 | $0.00 Strike: $100.85 | $0.00 |
DisclosureSEC source: 0001670138-26-000003 · form4-01302026_060106.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,140 Underlying: Common Stock · 18,140 shares Expires 2036-01-27 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,822 | $93.33 | $170,038.51 |
DisclosureSEC source: 0001670138-26-000002 · form4-01232026_050108.xml · nonDerivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,817 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001670138-26-000002 · form4-01232026_050108.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 3,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001670138-26-000002 · form4-01232026_050108.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 6,911 | $90.27 | $623,853.21 |
DisclosureSEC source: 0001670138-26-000001 · form4-01212026_040103.xml · nonDerivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,305 F3 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001670138-26-000001 · form4-01212026_040103.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F4 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001670138-26-000001 · form4-01212026_040103.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 67 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:55 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001954 · form4-01232025_100156.xml · derivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:55 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $47.98 | $0.00 |
DisclosureSEC source: 0001415889-25-001954 · form4-01232025_100156.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 21, 2025 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 21:21 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 6,969 | $45.86 | $319,598.34 |
DisclosureSEC source: 0001415889-25-001779 · form4-01212025_090130.xml · nonDerivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,649 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:21 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001779 · form4-01212025_090130.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:21 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001779 · form4-01212025_090130.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2024 Filed Nov 14, 2024 21:37 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 118 | $21.05 | $2,483.43 |
DisclosureSEC source: 0001415889-24-026873 · form4-11142024_091104.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 118 shares by the Reporting Person on November 8, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 00:42 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001561 · form4-01192024_120106.xml · derivative · entry 2 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 16, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 00:42 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $26.72 | $0.00 |
DisclosureSEC source: 0001415889-24-001561 · form4-01192024_120106.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-15 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest one year after January 16, 2024 (the "Vesting Commencement Date") and the balance of the shares will vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:18 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-023804 · doc4.xml · derivative · entry 3 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,256 Underlying: Common Stock · 4,000 shares Expires 2025-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the option vested on April 14, 2016 and the remaining shares vest in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:18 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 4,000 | $10.00 | $40,000.00 |
DisclosureSEC source: 0001209191-18-023804 · doc4.xml · nonDerivative · entry 2 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:18 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | Exercise / conversionCommon Stock | 4,000 | $2.06 | $8,240.00 |
DisclosureSEC source: 0001209191-18-023804 · doc4.xml · nonDerivative · entry 1 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:16 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-18-020445 · doc4.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-03-13 F1 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 19:37 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001209191-17-020655 · doc4.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-03-09 F1 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 23, 2016 Filed Sep 15, 2016 14:58 UTC Amendment | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 53,452 | $0.00 Strike: $15.89 | $0.00 |
DisclosureSEC source: 0001209191-16-141548 · doc4a.xml · derivative · entry 1 Quan Joanne · CIK 0001670138 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,452 Underlying: Common Stock · 53,452 shares Expires 2026-03-23 F1 · derivative.exercise_date: The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. F2 · derivative.exercise_date: The option grant was approved by Issuer's board of directors on March 22, 2016, subject to stockholder approval of an amendment to the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.